Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCTs031210134
JPRN-jRCTs031210134Completed未知

Safety and pharmacokinetic study of a new PET probe [18F]FEDAC in healthy adults

Tamura Kentaro0 sites10 target enrollmentStarted: June 8, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to < 65age old (—)
Sex
Male

Inclusion Criteria

  • •1. Healthy male subjects aged 20 or older and under 65 at the time of informed consent
  • •2. Subjects who provide written informed consent
  • •3. Subjects with BMI of less than 25

Exclusion Criteria

  • •1. Subjects who have severe or progressive complications.
  • •2. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent
  • •3. Subjects who have past history of severe drug hypersensitivity
  • •4. Subjects with drug or alcohol addiction
  • •5. Subjects who smoke
  • •6. Subjects who have received medication or used vitamins, herbal medicines, or supplements within 14 days prior to their visit
  • •7. Subjects who are claustrophobic
  • •8. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X-rays conducted as part of the annual medical check are excluded.
  • •9. Subjects who are considered to be inappropriate to participate in this study.

Investigators

Similar Trials

Recruiting
Phase 2
First in patients of a New PET Probe FEDACMalignant tumors(solid tumors)
JPRN-jRCTs031220192Tamura Kentaro30
Active, not recruiting
Not Applicable
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents
EUCTR2008-003917-29-GBGilead Sciences Incorporated24
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.
EUCTR2018-001516-30-BGGUERBET60
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance ImagingMedDRA version: 22.1Level: LLTClassification code 10029817Term: Nuclear magnetic resonance imaging brainSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10072232Term: Nuclear magnetic resonance imaging spinalSystem Organ Class: 100000004848
EUCTR2018-001516-30-PLGUERBET80
Active, not recruiting
Phase 1
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.
EUCTR2018-001516-30-SKGUERBET80